Key result
This review highlights approaches to block Hepatitis C virus IRES function using nucleic acid, peptide, and small molecule ligands, emphasizing subdomain IIa as a key target for translation inhibitors.
This review highlights the potential of targeting the HCV IRES subdomain IIa with small molecule inhibitors to block viral translation.
Answers are grounded in this paper and cite their sources.
May inform HCV antiviral design; leaves open clinical translation of subdomain IIa ligands.
The internal ribosome entry site (IRES) in the 5' untranslated region (UTR) of the hepatitis C virus (HCV) genome initiates translation of the viral polyprotein precursor. The unique structure and high sequence conservation of the 5' UTR render the IRES RNA a potential target for the development of selective viral translation inhibitors. Here, we provide an overview of approaches to block HCV IRES function by nucleic acid, peptide, and small molecule ligands. Emphasis will be given to the IRES subdomain IIa, which currently is the most advanced target for small molecule inhibitors of HCV translation. The subdomain IIa behaves as an RNA conformational switch. Selective ligands act as translation inhibitors by locking the conformation of the RNA switch. We review synthetic procedures for inhibitors as well as structural and functional studies of the subdomain IIa target and its ligand complexes.
No takes yet. Share an insight, caveat, or question.
Dibrov et al. (2013) conducted a review in Hepatitis C Virus. Hepatitis C Virus Translation Inhibitors was evaluated. This review highlights approaches to block Hepatitis C virus IRES function using nucleic acid, peptide, and small molecule ligands, emphasizing subdomain IIa as a key target for translation inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: